Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- MBC
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
This is an open-label, randomized, multicenter Phase 3 study to compare the efficacy and
safety of sacituzumab govitecan versus TPC in subjects with metastatic or locally recurrent
inoperable HR+/HER2- MBC, after failure of at least 2, and no more than 4, prior chemotherapy
regimens for metastatic disease.